Table IV.
Association between MDM2 40-bp I/D and TP53 16-bp I/D polymorphisms with clinicopathological parameters in patients with prostate cancer.
| MDM2 40-bp I/D | TP53 16-bp I/D | |||||||
|---|---|---|---|---|---|---|---|---|
| Factors | II | ID | DD | P-value | DD | DI | II | P-value |
| Age at diagnosis (years), n | 0.976 | 0.529 | ||||||
| ≤65 | 30 | 45 | 3 | 25 | 40 | 13 | ||
| >65 | 9 | 15 | 1 | 11 | 10 | 4 | ||
| Stage | 0.152 | 0.241 | ||||||
| pT1 | 3 | 5 | 0 | 4 | 3 | 1 | ||
| pT2a | 5 | 12 | 3 | 7 | 6 | 7 | ||
| pT2b | 3 | 4 | 0 | 2 | 4 | 1 | ||
| pT2c | 18 | 21 | 0 | 16 | 18 | 5 | ||
| pT3a | 1 | 6 | 1 | 2 | 4 | 2 | ||
| pT3b | 9 | 12 | 0 | 5 | 15 | 1 | ||
| PSA level at diagnosis (ng/ml), n | 0.647 | 0.538 | ||||||
| ≤4 | 1 | 0 | 0 | 1 | 0 | 0 | ||
| 4–10 | 18 | 29 | 1 | 19 | 21 | 8 | ||
| >10 | 20 | 31 | 3 | 16 | 29 | 9 | ||
| Gleason score, n | 0.475 | 0.674 | ||||||
| ≤7 | 32 | 46 | 4 | 30 | 38 | 14 | ||
| >7 | 7 | 14 | 0 | 6 | 12 | 3 | ||
| Perineural invasion, n | 0.886 | 0.878 | ||||||
| Positive | 22 | 36 | 2 | 21 | 30 | 9 | ||
| Negative | 17 | 24 | 2 | 15 | 20 | 8 | ||
| Surgical margin, n | 0.925 | 0.035 | ||||||
| Positive | 16 | 24 | 2 | 13 | 26 | 3 | ||
| Negative | 23 | 36 | 2 | 23 | 24 | 14 | ||
MDM2, murine double minute-2; TP53, tumor protein 53; I, insertion; D, deletion; PSA, prostate specific antigen. pT1, pT2a, pT2b, pT2c, pT3a and pT3b are clinical stages of prostate cancer.